147 related articles for article (PubMed ID: 32142836)
1. Histopathological features of epithelioid malignant pleural mesotheliomas in patients with extended survival.
Paajanen J; Laaksonen S; Kettunen E; Ilonen I; Vehmas T; Salo J; Räsänen J; Sutinen E; Ollila H; Mäyränpää MI; Myllärniemi M; Wolff H
Hum Pathol; 2020 Apr; 98():110-119. PubMed ID: 32142836
[TBL] [Abstract][Full Text] [Related]
2. Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.
Rosen LE; Karrison T; Ananthanarayanan V; Gallan AJ; Adusumilli PS; Alchami FS; Attanoos R; Brcic L; Butnor KJ; Galateau-Sallé F; Hiroshima K; Kadota K; Klampatsa A; Stang NL; Lindenmann J; Litzky LA; Marchevsky A; Medeiros F; Montero MA; Moore DA; Nabeshima K; Pavlisko EN; Roggli VL; Sauter JL; Sharma A; Sheaff M; Travis WD; Vigneswaran WT; Vrugt B; Walts AE; Tjota MY; Krausz T; Husain AN
Mod Pathol; 2018 Apr; 31(4):598-606. PubMed ID: 29327706
[TBL] [Abstract][Full Text] [Related]
3. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
4. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.
Kadota K; Suzuki K; Colovos C; Sima CS; Rusch VW; Travis WD; Adusumilli PS
Mod Pathol; 2012 Feb; 25(2):260-71. PubMed ID: 21983936
[TBL] [Abstract][Full Text] [Related]
5. Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies.
Habougit C; Trombert-Paviot B; Karpathiou G; Casteillo F; Bayle-Bleuez S; Fournel P; Vergnon JM; Tiffet O; Péoc'h M; Forest F
Virchows Arch; 2017 Jun; 470(6):639-646. PubMed ID: 28349237
[TBL] [Abstract][Full Text] [Related]
6. Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting: An External Validation Study of 563 Cases.
Zhang YZ; Brambilla C; Molyneaux PL; Rice A; Robertus JL; Jordan S; Lim E; Lang-Lazdunski L; Begum S; Dusmet M; Anikin V; Beddow E; Finch J; Asadi N; Popat S; Cookson WOC; Moffatt MF; Nicholson AG
Am J Surg Pathol; 2020 Mar; 44(3):347-356. PubMed ID: 32045387
[TBL] [Abstract][Full Text] [Related]
7. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
Ghanim B; Klikovits T; Hoda MA; Lang G; Szirtes I; Setinek U; Rozsas A; Renyi-Vamos F; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz T; Dome B; Hegedus B
Br J Cancer; 2015 Mar; 112(5):783-92. PubMed ID: 25633038
[TBL] [Abstract][Full Text] [Related]
8. Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
Vigneswaran WT; Kircheva DY; Ananthanarayanan V; Watson S; Arif Q; Celauro AD; Kindler HL; Husain AN
Ann Thorac Surg; 2017 Mar; 103(3):962-966. PubMed ID: 27765170
[TBL] [Abstract][Full Text] [Related]
9. Impact on survival of nuclear atypia in epithelioid malignant mesothelioma.
Mlika M; Limam M; Benzarti A; Mezni F
Adv Respir Med; 2019; 87(2):90-95. PubMed ID: 31038719
[TBL] [Abstract][Full Text] [Related]
10. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma.
Alchami FS; Attanoos RL; Bamber AR
J Clin Pathol; 2017 Feb; 70(2):179-182. PubMed ID: 27798081
[TBL] [Abstract][Full Text] [Related]
11. Histopathological typing in diffuse malignant epithelioid mesothelioma: implication for prognosis and molecular basis.
Forest F; Laville D; Habougit C; Corbasson M; Bayle-Bleuez S; Tissot C; Fournel P; Tiffet O; Péoc'h M
Pathology; 2021 Oct; 53(6):728-734. PubMed ID: 33965253
[TBL] [Abstract][Full Text] [Related]
12. Combined grade and nuclear grade are prognosis predictors of epithelioid malignant peritoneal mesothelioma: a multi-institutional retrospective study.
Benzerdjeb N; Dartigues P; Kepenekian V; Valmary-Degano S; Mery E; Averous G; Chevallier A; Laverriere MH; Villa I; Sallé FG; Villeneuve L; Glehen O; Isaac S; Hommell-Fontaine J;
Virchows Arch; 2021 Nov; 479(5):927-936. PubMed ID: 34169365
[TBL] [Abstract][Full Text] [Related]
13. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma.
Kadota K; Suzuki K; Sima CS; Rusch VW; Adusumilli PS; Travis WD
J Thorac Oncol; 2011 May; 6(5):896-904. PubMed ID: 21358344
[TBL] [Abstract][Full Text] [Related]
14. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
[TBL] [Abstract][Full Text] [Related]
15. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
[TBL] [Abstract][Full Text] [Related]
16. Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2-tier nuclear grade.
Zhang YZ; Brambilla C; Molyneaux PL; Rice A; Robertus JL; Jordan S; Lim E; Lang-Lazdunski L; Begum S; Dusmet M; Anikin V; Beddow E; Finch J; Asadi N; Popat S; Quesne JL; Husain AN; Cookson WOCM; Moffatt MF; Nicholson AG
Histopathology; 2020 Sep; 77(3):423-436. PubMed ID: 32333813
[TBL] [Abstract][Full Text] [Related]
17. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
18. Primary pleural epithelioid mesothelioma of clear cell type: a case report and review of current literature.
Gkogkou C; Samitas K; Foteinou M
Ultrastruct Pathol; 2011 Dec; 35(6):267-70. PubMed ID: 21978187
[TBL] [Abstract][Full Text] [Related]
19. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
[TBL] [Abstract][Full Text] [Related]
20. The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma.
Chou A; Toon CW; Clarkson A; Sheen A; Sioson L; Gill AJ
Histopathology; 2018 Feb; 72(3):509-515. PubMed ID: 28889523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]